Garfield David H, Cadranel Jacques L, Wislez Marie, Franklin Wilbur A, Hirsch Fred R
Department of Medicine, University of Colorado Health Sciences Center, Aurora, Colorado 80010, USA.
J Thorac Oncol. 2006 May;1(4):344-59.
Bronchioloalveolar carcinoma (BAC) develops from terminal bronchiolar and acinar epithelia, growing along alveolar septa but without evidence of vascular or pleural involvement. A final diagnosis of BAC can only be achieved from a surgical specimen. Problematically, BAC may exhibit multifocal involvement by means of diffuse aerogenous metastatic spread, making this definition inapplicable for patients with stage IIIB to IV disease from whom only small size biopsy or cytological specimens are obtained. The recent interest and potential importance of BAC and the related peripheral adenocarcinoma (ADC), mixed subtype, is attributable to mounting evidence that some, perhaps many, of what are called peripheral ADCs have arisen from and often contain BAC. BAC, in turn, appears to arise from smaller peripheral nodules, called atypical adenomatous hyperplasia. These developments could account for part of the increase in ADCs noted in some countries, in particular, in East Asia. Interest also stems from the observation that advanced ADC, often with BAC features, are responding in surprising fashion to tyrosine kinase inhibitors. Furthermore, some of the more rapid, dramatic, and durable responses occur when specific mutations in the epidermal growth factor receptor are present. Clinical characteristics often differ from other types of non-small cell lung cancers. These include frequent female occurrence, especially in East Asians; no or less smoking history; an often indolent course; distinctive chest computed tomographic findings; frequent presentation as an asymptomatic, sometimes small, peripheral nodule(s)/mass; multifocal/synchronous primary tumors; and less frequently as pneumonic-type consolidation or diffuse, inoperable lesions, the latter two often with bronchorrhea, and with chest-only disease. Relapses also are predominantly pulmonary, perhaps related to aerogenous spread, and responsible for mortality. Lobectomy is the treatment of choice for cure, even with pneumonic consolidation, but lesser procedures such as wedge resection or segmentectomy may be considered for what might be multifocal, synchronous primary tumors and for pulmonary relapses. Because of frequent lung-only recurrences, lung transplantation, although performed rarely, may hold promise.
细支气管肺泡癌(BAC)起源于终末细支气管和腺泡上皮,沿肺泡间隔生长,但无血管或胸膜受累证据。BAC的最终诊断只能通过手术标本实现。问题在于,BAC可能通过弥漫性气源性转移扩散而表现为多灶性受累,这使得该定义不适用于仅获得小尺寸活检或细胞学标本的ⅢB期至Ⅳ期疾病患者。最近对BAC以及相关的外周腺癌(ADC)混合亚型的关注及其潜在重要性,归因于越来越多的证据表明,一些(也许是许多)所谓的外周ADC起源于BAC且通常包含BAC。反过来,BAC似乎起源于较小的外周结节,即非典型腺瘤样增生。这些进展可能是一些国家(特别是东亚)ADC发病率增加的部分原因。关注还源于这样的观察结果,即晚期ADC(通常具有BAC特征)对酪氨酸激酶抑制剂有惊人的反应。此外,当表皮生长因子受体存在特定突变时,会出现一些更快速、显著和持久的反应。其临床特征通常与其他类型的非小细胞肺癌不同。这些特征包括女性发病率高,尤其是东亚女性;无吸烟史或吸烟史较少;病程通常较为惰性;胸部计算机断层扫描有独特表现;常表现为无症状的、有时较小的外周结节/肿块;多灶性/同步原发性肿瘤;较少表现为肺炎型实变或弥漫性、无法手术的病变,后两者常伴有支气管溢液,且仅累及胸部。复发也主要在肺部,可能与气源性扩散有关,并导致死亡。肺叶切除术是治愈的首选治疗方法,即使存在肺炎性实变,但对于可能是多灶性、同步原发性肿瘤以及肺部复发的情况,也可考虑采用楔形切除术或肺段切除术等较小的手术。由于经常仅在肺部复发,肺移植虽然很少进行,但可能有前景。